PharmiWeb2h
Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative join forces to combat vision loss from diabetes
Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative (MTM Vision) today jointly announce the start of a long-term ...
With $66 million R&D center, Boehringer Ingelheim fulfills economic development pledge to state
The $66 million project is part of the company's obligation made to the state after it moved here to invest a total of $120 ...
dvm36013d
Boehringer Ingelheim announces research and development facility expansion
The state-of-the-art research and development center in Georgia will help improve the health and wellbeing of animals ...
FierceBiotech12d
Boehringer Ingelheim drops obesity drug from Gubra partnership
Boehringer Ingelheim has halted development of an obesity drug from Gubra that it originally pledged to advance back in 2017, ...
pharmaphorum8d
Boehringer bags first approval for rare skin disease drug
German drugmaker Boehringer Ingelheim has its first regulatory approval ... The FDA has cleared the IL-36 receptor inhibitor under the Spevigo brand name to treat the devastating eruptions of ...
German pharmaceutical company sees great benefits from CIIE's spillover effect
STORY German pharmaceutical company sees great benefits from CIIE spillover effectSHOOTING TIME Recent footageDATELINE Nov 10 2024LENGTH 00011 ...
FiercePharma12d
Boehringer, Amgen, Novartis sweep corporate reputation rankings among cardiovascular patient groups
A new survey shows that three Big Pharmas have stolen the hearts of patient groups representing nearly 1 million people with cardiovascular conditions. | A new survey shows that three Big Pharmas have ...
‘Sick day’ on the clock: CT Biopharma firm expands patient simulations to spark creativity, empathy
Spending the day facing the challenges of kidney patients helps workers at a CT pharmaceutical company understand disease and ...
The Pharma Letter9d
Boehringer mental health tie-up worth up to $126.5 million to Broad Institute
Privately-held German drugmaker Boehringer Ingelheim and researchers from the Stanley Center for Psychiatric Research at the ...
pharmaphorum5d
Boehringer says R&D pipeline is the best in its long history
Boehringer Ingelheim says it is on track to launch ... The launch environment for pharmaceutical industry products is evolving at pace with new scientific discoveries and shifting engagement ...
Boehringer Ingelheim Limited: Boehringer Ingelheim and the Mary Tyler Moore Vision Initiative join forces to combat vision loss from diabetes
More than 530 million people worldwide living with diabetes are at risk for developing diabetic retinal disease (DRD), the leading cause of blindness in working-age adults. 1·DRD is a growing epidemic ...